The Patent Finder

Amygdala Neurosciences, Inc.

Also on record
Records under this name other than the patents Amygdala Neurosciences, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.

Showing 1 to 5 of 5 · Back to Amygdala Neurosciences, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,673,966ALDH-2 Inhibitors in the Treatment of Addiction
Lapsed on the fee record
Ended Mar 18, 2026 · High confidence
Lapsed on the fee recordEnded Mar 18, 2026High confidence
US 9,610,299Compounds for the Treatment of Addiction
Lapsed on the fee record
Ended Apr 4, 2025 · Medium confidence
Lapsed on the fee recordEnded Apr 4, 2025Medium confidence
US 8,158,810ALDH-2 Inhibitors in the Treatment of Addiction
Lapsed on the fee record
Ended Apr 17, 2024 · Low confidence
Lapsed on the fee recordEnded Apr 17, 2024Low confidence
US 10,507,215Compounds for the Treatment of Addiction
Lapsed on the fee record
Ended Dec 17, 2023 · High confidence
Lapsed on the fee recordEnded Dec 17, 2023High confidence
US 7,951,813Quinazolinone Derivatives as ALDH-2 Inhibitors
Lapsed on the fee record
Ended May 31, 2023 · High confidence
Lapsed on the fee recordEnded May 31, 2023High confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited